Skip to main content
Fig. 6 | BMC Pharmacology and Toxicology

Fig. 6

From: Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024)

Fig. 6

External validation from the JADER database. (A) Annual distribution of adverse drug event (ADE) reports spanning from 2010 to the first quarter of 2024. (B) Baseline information for ADE reports for ganirelix. (C) Signal detection at the SOC level: A forest plot representing reporting odds ratio (ROR) values along with their 95% confidence interval. (D) Signal detection at the PT level. The forest plot highlights the four positive PTs that meet the signal strength thresholds across all four methods. (E) Time to onset (TTO) analysis at the PT level. (F) The Kaplan-Meier curve depicts the cumulative incidence for the four PTs. JADER, Japanese Adverse Drug Event Report; SOC, system organ class; PT, preferred term; IQR, interquartile range

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us